Sarepta is facing a shareholder lawsuit over ELEVIDYS-related deaths. Robbins LLP cites safety risks and stock losses.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hund ...

About Robbins LLP : A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LL have been dedicated to helping shareholders recover losses, improve corporate governance ...

The grandmother of a four-year-old boy from Co Kilkenny diagnosed with a life-limiting genetic disorder has vowed to keep ...

The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...

Therefore, we have recommended halting treatment with Elevidys in non-ambulatory patients with immediate effect." Elevidys has been on the US market since 2023, with its label expanded last year.

Duchenne Muscular Dystrophy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook ...

The FDA has subsequently launched an investigation, and investors are understandably spooked about the outlook for Elevidys and Sarepta. SRPT stock is down 85.9% overall in 2025.